Trabecular quality and cellular characteristics of normal, diabetic, and charcot bone.

Charcot neuroarthropathy (CN) is a disabling and devastating condition that affects many neuropathic diabetic patients. It can lead to foot deformity, ulceration, and lower extremity amputation. The pathogenesis of CN is not clear, but 1 possible predisposing factor is increased bone turnover and increased osteoclastic activity. Although the affect of diabetes on bone is not entirely clear, studies have shown increased bone fragility in diabetics with neuropathy. The purpose of the present study was to compare the bone quality histologic findings and trabecular histomorphometry, including the cellular characteristics, between normal subjects (N = 7), diabetics without CN (N = 8), and diabetics with CN (N = 8). Histologically, the bone in diabetics with CN displayed an inflammatory, myxoid infiltrate. We also observed a statistically significant decrease in the number of trabeculae in bone in diabetics with CN compared with normal controls (p < .02). However, the difference between the trabeculae in diabetics with CN and diabetics without CN was not statistically significant (p > .05). Histologically, the CN bone appeared to be infiltrated with inflammatory myxoid tissue and had a disorganized trabecular pattern compared with diabetic bone without CN and normal bone. The trabeculae in patients with CN appeared to have poor quality characteristics compared with that of the other groups. The findings from the present study might indicate that diabetes mellitus bone is fragile, and the decrease in the cellular component might impair the reparative process in those with CN foot.

[1]  M. Bouxsein,et al.  A bone structural basis for fracture risk in diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[2]  D. Sinacore,et al.  Inflammatory Osteolysis in Diabetic Neuropathic (Charcot) Arthropathies of the Foot , 2008, Physical Therapy.

[3]  L. Harkless,et al.  Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. , 2008, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[4]  T. Therneau,et al.  Fracture Risk in Type 2 Diabetes: Update of a Population‐Based Study , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  D. Sinacore,et al.  Mid foot kinetics characterize structural polymorphism in diabetic foot disease. , 2008, Clinical biomechanics.

[6]  L. Saketkoo,et al.  Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up. , 2008, The American journal of the medical sciences.

[7]  M. Pinzur.  Neutral Ring Fixation for High-Risk Nonplantigrade Charcot Midfoot Deformity , 2007, Foot & ankle international.

[8]  P. Holstein,et al.  Arthrodesis With External Fixation in the Unstable or Misaligned Charcot Ankle in Patients With Diabetes Mellitus , 2007, The international journal of lower extremity wounds.

[9]  D. Thordarson,et al.  Tibiotalocalcaneal Arthrodesis Using a Dynamically Locked Retrograde Intramedullary Nail , 2006, Foot & ankle international.

[10]  N. Baldini,et al.  Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. , 2006, The Journal of bone and joint surgery. American volume.

[11]  S. van der Linden,et al.  The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. , 2006, Arthritis and rheumatism.

[12]  A. Foster,et al.  Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[13]  M. Zaidi.  Neural surveillance of skeletal homeostasis. , 2005, Cell metabolism.

[14]  J. Gamonal,et al.  Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. , 2004, Journal of periodontology.

[15]  A. M. Jacobs,et al.  Bisphosphonates for the treatment of Charcot neuroarthropathy. , 2004, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[16]  H. Ozawa,et al.  Calcitonin gene‐related peptide (CGRP)‐containing nerve fibers in bone tissue and their involvement in bone remodeling , 2002, Microscopy research and technique.

[17]  Daniel C. Farber,et al.  Single Stage Correction with External Fixation of the Ulcerated Foot in Individuals with Charcot Neuroarthropathy , 2002, Foot & ankle international.

[18]  L. Brenner,et al.  Use of electrostimulation in the treatment of diabetic neuroarthropathy. , 2000, Journal of the American Podiatric Medical Association (Print).

[19]  W. Jeffcoate,et al.  The Charcot foot , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[20]  T. Rönnemaa,et al.  Bone mineral density in patients with type 1 and type 2 diabetes. , 1999, Diabetes care.

[21]  J. Hanft,et al.  The role of combined magnetic field bone growth stimulation as an adjunct in the treatment of neuroarthropathy/Charcot joint: an expanded pilot study. , 1998, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[22]  D. Armstrong,et al.  Monitoring healing of acute Charcot's arthropathy with infrared dermal thermometry. , 1997, Journal of rehabilitation research and development.

[23]  W. F. Todd,et al.  The Natural History of Acute Charcot’s Arthropathy in a Diabetic Foot Specialty Clinic , 1997, Journal of the American Podiatric Medical Association.

[24]  J. Adams,et al.  Osteopenia, Neurological Dysfunction, and the Development of Charcot Neuroarthropathy , 1995, Diabetes Care.

[25]  R. Busse,et al.  CGRP enhances induction of NO synthase in vascular smooth muscle cells via a cAMP-dependent mechanism. , 1994, The American journal of physiology.

[26]  X. Holy,et al.  Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. , 1994, Endocrinology.

[27]  M. Myerson,et al.  Salvage, with arthrodesis, in intractable diabetic neuropathic arthropathy of the foot and ankle. , 1993, The Journal of bone and joint surgery. American volume.

[28]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987 .

[29]  J. Olefsky,et al.  Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. , 1986, Endocrinology.

[30]  P. Watkins,et al.  Increased uptake of bone radiopharmaceutical in diabetic neuropathy. , 1985, The Quarterly journal of medicine.

[31]  P. Lips,et al.  Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age , 1978, Calcified Tissue Research.

[32]  S. Sinha,et al.  NEURO-ARTHROPATHY (CHARCOT JOINTS) IN DIABETES MELLITUS , 1972 .

[33]  S. Cummings,et al.  Older women with diabetes have an increased risk of fracture: a prospective study. , 2001, The Journal of clinical endocrinology and metabolism.

[34]  E. Balint,et al.  Glucose-induced inhibition of in vitro bone mineralization. , 2001, Bone.

[35]  J. Charcot.  Sur quelques arthropathies qui paraissent dépendre d'une lésion du cerveau ou de la moelle épinière , 1868 .